200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study
JACC: Cardiovascular Interventions · 2026-03 · 19 (5) · S27
DOI: 10.1016/j.jcin.2026.01.090 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-03. Verfasst von Ibrahim Halil Inanc und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Inanc, I. H., Yimit, A., Darwish, M., Inanc, F. A., Aksu, C., Irani, S., & Ratliff, D. (2026). 200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study. JACC: Cardiovascular Interventions, 19(5), S27. https://doi.org/10.1016/j.jcin.2026.01.090
Vancouver
Inanc IH, Yimit A, Darwish M, Inanc FA, Aksu C, Irani S, et al. 200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study. JACC: Cardiovascular Interventions. 2026;19(5):S27. doi:10.1016/j.jcin.2026.01.090
BibTeX
@article{Inanc2026,
author = {Inanc, Ibrahim Halil and Yimit, Asigul and Darwish, Mohamed and Inanc, Fulden Akyuz and Aksu, Cagri and Irani, Safina and Ratliff, Daniel},
title = {200.09 DOACS vs Warfarin After TAVR in Atrial Fibrillation: A Global Propensity-Matched Outcomes Study},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {5},
pages = {S27},
doi = {10.1016/j.jcin.2026.01.090}
}
EUVIMED